Independent · evidence-based · non-judgmentalDraft · pending medical review
Not yet medically reviewed — information on this site is in preparation and has not been verified by a medical reviewer.
Drug index / Opioid / Kratom
Opioid

Kratom

Kratom is a Southeast Asian plant whose leaves act as a mild stimulant at low doses and produce opioid-like effects at higher doses; it carries real dependence and toxicity risks and is federally unscheduled but banned in several U.S. states.

Overview

Kratom (Mitragyna speciosa) is a tree native to Southeast Asia, in the coffee family, whose leaves have been used traditionally in the region to relieve fatigue, pain, and opioid withdrawal. The leaves contain dozens of bioactive alkaloids; the two most studied are mitragynine and 7-hydroxymitragynine. People in the United States typically use dried, powdered leaf in capsules, brewed as tea, or as concentrated extracts. At lower doses kratom tends to produce mild stimulant-like effects, while at higher doses its effects are more opioid-like — sedation, pain relief, and euphoria. The U.S. Food and Drug Administration has not approved kratom for any medical use and considers it an unapproved drug and an unsafe food additive; it is not the same as an FDA-reviewed medication, and product contents and potency vary widely between brands.

Source: NIDA; FDA; Congressional Research Service

Chemistry & mechanism of action

Kratom's effects come mainly from its alkaloids acting on the brain's opioid system. Mitragynine, the most abundant alkaloid in the leaf, is converted in the body into 7-hydroxymitragynine, and both activate mu-opioid receptors — the same receptors targeted by drugs like morphine and oxycodone — though research suggests their effects only partly resemble those of conventional opioids. Mitragynine also appears to interact with adrenergic, serotonin, and dopamine receptors, which may explain the stimulant-like, arousing effects some people report at lower doses. Because the active compounds engage opioid receptors, kratom can produce tolerance, physical dependence, and withdrawal, and its effects and risks can shift depending on dose and on how concentrated a given product is.

Source: NIDA; peer-reviewed pharmacology literature

Effects

Reported effects depend heavily on dose. At lower doses people often describe increased energy, alertness, talkativeness, and sociability. At higher doses the effects shift toward those associated with opioids: pain relief, calm, sedation, and euphoria. Commonly reported unwanted effects include nausea, vomiting, constipation, itching, sweating, dizziness, dry mouth, and increased urination. Heavy or long-term use is associated with weight loss, fatigue, and — in some reports — liver problems. Regular use can lead to dependence, and stopping after sustained use can produce withdrawal symptoms similar to mild opioid withdrawal, such as irritability, muscle aches, runny nose, and craving.

Source: NIDA; FDA

Risks & harms

Although kratom is often marketed as a natural and therefore safe product, it carries real risks. Regular use can cause dependence and an opioid-like withdrawal syndrome. Kratom has been involved in poison-control calls and in deaths, though many reported deaths involved other substances taken at the same time — combining kratom with opioids, benzodiazepines, alcohol, or other depressants is particularly dangerous and can increase the risk of sedation and slowed breathing. Reported harms include liver injury, seizures, rapid heart rate, high blood pressure, and, with very high doses, the opioid risk of respiratory depression. A major current concern is concentrated 7-hydroxymitragynine products (tablets, gummies, shots) that are far more potent than natural leaf and behave much more like strong opioids. Product quality is inconsistent, and kratom products have been found contaminated (for example with Salmonella or heavy metals) or adulterated with other drugs. If someone may have overdosed or taken a dangerous combination, call 911; for poisoning call Poison Control at 1-800-222-1222. For help with dependence, SAMHSA's helpline is 1-800-662-4357.

Source: FDA; NIDA; Congressional Research Service

Subjective effects

low dose → alertness, energy, talkativeness, sociability; high dose → opioid-like sedation + euphoria

Onset

5–10 min

Duration

2–5 hr

Harmful effects

nausea, itching, sweating, dry mouth, constipation; addiction + withdrawal; long-term anorexia, weight loss, insomnia, hepatotoxicity; kratom psychosis; overdose + fatalities reported

Medicinal use

none in US (used traditionally + self-treatment of opioid withdrawal)

History

used by SE Asian laborers for centuries; opium substitute

Prevalence

NFLIS >4,000 mitragynine reports since 2010

Images

Visual references coming soon.

If it’s too intense

If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.

  • Get to a calm, safe space with someone you trust who is sober and can stay with you.
  • Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
  • Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
  • Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
  • A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
  • Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.

With opioids, slowed or stopped breathing is the emergency — if available, give naloxone and call 911 immediately; it can be given while you wait for help.

Call 911 (or Poison Control, 1-800-222-1222) right away for chest pain, a very high body temperature, a seizure, unconsciousness, or severe confusion. These are medical emergencies, not something to wait out.

Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.

Forensic dossier

Draft · every field is source-cited or marked “Unknown — pending review”

Identity

PubChem CID
N/A — no single PubChem compound (mixture/class/plant/concept)
IUPAC name
N/A — no single PubChem compound (mixture/class/plant/concept)
Molecular formula
N/A — no single PubChem compound (mixture/class/plant/concept)
SMILES
N/A — no single PubChem compound (mixture/class/plant/concept)
InChIKey
N/A — no single PubChem compound (mixture/class/plant/concept)
Synonyms / aliases
mitragyna speciosa, ketum

Composition

Composition
Unknown — pending review (no single compound; needs an epidemiology / composition source)

Physical / pill characteristics

Dosage form
Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
Route
Unknown — pending review
Shape
Unknown — pending review
Color
Unknown — pending review
Imprint
Unknown — pending review
Score
Unknown — pending review

Scheduling & legal status

US schedule
Unknown — pending review
International
See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA · retrieved 2026-06-18

Effects

Effects
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Risks

Risks
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Interactions

Interactions
Unknown — pending review

Dosage

Pending medical reviewer

Sources

← Back to the drug index